TSXV:ZKL.H - Post by User
Comment by
TSX-Newson Jan 09, 2014 3:13pm
71 Views
Post# 22075206
RE:RE:RE:RE:20-30 cents
RE:RE:RE:RE:20-30 centsOr how about like SSS Baggie? Or FSW or NCI? I take the good with the bad but you're cherry picking one mediocre pick and ignoring all the other great ones.
https://tsxnews.blogspot.ca/2013/11/fda-grants-orphan-drug-status.html FDA Grants Orphan Drug Status Which Goes Unnoticed on the TSX Venture and Stockhouse Starts Recommending Tech Stocks
SSS.V CURRENT PRICE: $0.32 SSS.V 3-MONTH TARGET PRICE: $0.50 3-MONTH UPSIDE POTENTIAL: 56% SHARES OUTSTANDING: 42,504,687 MARKET CAP: 13,601,500
November 2, 2013
Stem Cell Therapeutics Corp. (SSS)
Exchange: TSX Venture Exchange |  |
$
0.475 
Jan 9, 2014, 2:56 PM EST
Change: 0.01 (2.15%)
Volume: 686,052
Day Low
0.465
Day High
0.495
ZMD has it's own issues and still bullish on that. But ZKL is undeniably profitable and undeniably growing.